Skip to main content

Advertisement

SpringerLink
Log in

Association of antibody to E2 protein of human papillomavirus and p16INK4A with progression of HPV-infected cervical lesions

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Human papillomavirus (HPV) E2 and L1 proteins are expressed in cervical cells during the lytic stage of infection. Overexpression of p16INK4A is a biomarker of HPV-associated cervical neoplasia. This study investigated antibodies to HPV16 E2, HPV16 L1, and p16INK4A in sera from women with no squamous intraepithelial lesion (No-SIL) of the cervix, low-grade SIL, high-grade SIL, and cervical squamous cell carcinoma (SCC). HPV DNA was detected by polymerase chain reaction. Anti-E2, -L1, and -p16INK4A antibodies in sera were determined by western blot. Among 116 samples, 69 (60%) were HPV DNA-positive. Percentages seropositive for anti-E2, -L1, and -p16INK4A antibodies were 39.6, 22.4, and 23.3%, respectively. Anti-E2 antibody was significantly correlated with HPV DNA-positive cases. Eighty-seven women (75%) were regarded as infected with HPV, having at least one positive result from HPV DNA, L1, or E2 antibody. Antibody to p16INK4A was associated with HPV infection (odds = 5.444, 95% CI 1.203–24.629, P = 0.028) and precancerous cervical lesions (odds = 5.132, 95% CI 1.604–16.415, P = 0.006). Interestingly, the concurrent detection of anti-E2 and -p16INK4A antibodies was significantly associated with HPV infection (odds = 1.382, 95% CI 1.228–1.555, P = 0.044). These antibodies might be good candidate biomarkers for monitoring HPV-associated cervical lesion development to cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosales R, López-Contreras M, Cortes RR. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA. J Med Virol. 2001;65:736–44.

    Article  PubMed  CAS  Google Scholar 

  2. Coutlée F, Rouleau D, Ferenczy A, Franco E. The laboratory diagnosis of genital human papillomavirus infections. Can J Infect Dis Med Microbiol. 2005;16:83–91.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau M-C, Désy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415–23.

    Article  PubMed  CAS  Google Scholar 

  4. Scheurer M, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005;15:727–46.

    Article  PubMed  CAS  Google Scholar 

  5. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9.

    Article  PubMed  CAS  Google Scholar 

  6. Bontkes HJ, de Gruijl TD, Walboomers J, Schiller JT, Dillner J, Helmerhorst T, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol. 1999;80:409–17.

    Article  PubMed  CAS  Google Scholar 

  7. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384:410–4.

    Article  PubMed  CAS  Google Scholar 

  8. Qian J, Dong Y, Pang YYS, Ibrahim R, Berzofsky JA, Schiller JT, et al. Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer. 2006;118:3022–9.

    Article  PubMed  CAS  Google Scholar 

  9. van Poelgeest MI, Nijhuis ER, Kwappenberg K, Hamming IE, Wouter Drijfhout J, Fleuren GJ, et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer. 2006;118:675–83.

    Article  PubMed  CAS  Google Scholar 

  10. Anderson KS, Dahlstrom KR, Cheng JN, Alam R, Li G, Wei Q, et al. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncol. 2015;51:662–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Combes JD, Pawlita M, Waterboer T, Hammouda D, Rajkumar T, Vanhems P, et al. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. Int J Cancer. 2014;135:2453–61.

    Article  PubMed  CAS  Google Scholar 

  12. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 2002;62:472–9.

    PubMed  Google Scholar 

  13. Kreimer AR, Brennan P, Lang Kuhs KA, Waterboer T, Clifford G, Franceschi S, et al. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol. 2015;33:877–84.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lehtinen M, Leminen A, Kuoppala T, Tiikkainen M, Lehtinen T, Lehtovirta P, et al. Pre-and posttreatment serum antibody responses to HPV 16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma. J Med Virol. 1992;37:180–6.

    Article  PubMed  CAS  Google Scholar 

  15. Brandsma JL, Shlyankevich M, Zelterman D, Su Y. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine. 2007;25:6158–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375:503–6.

    Article  PubMed  CAS  Google Scholar 

  17. Reuschenbach M, Waterboer T, Wallin K-L, Einenkel J, Dillner J, Hamsikova E, et al. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer. 2008;123:2626–31.

    Article  PubMed  CAS  Google Scholar 

  18. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38:2229–42.

    Article  Google Scholar 

  19. Wentzensen NA, Kaufmann A, Reuschenbach M, Linnebacher M, Doeberitz MVK. P16 INK4a is a tumor autoantigen in HR-HPV induced cancers. AACR. 2005;46:5140.

    Google Scholar 

  20. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer Cytopathol. 2008;114:83–8.

    Article  Google Scholar 

  21. Xue Y, Bellanger S, Zhang W, Lim D, Low J, Lunny D, et al. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res. 2010;70:5316–25.

    Article  PubMed  CAS  Google Scholar 

  22. Xue Y, Toh SY, He P, Lim T, Lim D, Pang CL, et al. HPV16-E2 induces prophase arrest and activates the cellular DNA damage response in vitro and in precursor lesions of cervical carcinoma. Oncotarget. 2015;6:34979.

    PubMed  PubMed Central  Google Scholar 

  23. Kim HJ, Kim SY, Lim SJ, Kim JY, Lee SJ, Kim H-J. One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif. 2010;70:68–74.

    Article  PubMed  CAS  Google Scholar 

  24. Stanley M, Pett M, Coleman N. HPV: from infection to cancer. Biochem Soc Trans. 2007;35:1456–60.

    Article  PubMed  CAS  Google Scholar 

  25. Stanley M. HPV-immune response to infection and vaccination. Infect Agent Cancer. 2010;5:19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Madrid-Marina V, Torres-Poveda K, López-Toledo G, García-Carrancá A. Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res. 2009;40:471–7.

    Article  PubMed  CAS  Google Scholar 

  27. Combita A-L, Touzé A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol. 2002;76:6480–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Matsumoto K, Yoshikawa H, Yasugi T, Nakagawa S, Kawana K, Takeoka A, et al. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: Case-control study of cervical intraepithelial neoplasia in Japan. J Med Virol. 2003;69:441–6.

    Article  PubMed  CAS  Google Scholar 

  29. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol. 1997;4:122–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  30. Pang CL, Thierry F. Human papillomavirus proteins as prospective therapeutic targets. Microb Pathog. 2013;58:55–65.

    Article  PubMed  CAS  Google Scholar 

  31. Spriggs CC, Laimins LA. Human papillomavirus and the DNA damage response: exploiting host repair pathways for viral replication. Viruses. 2017;9:1–14.

    Article  Google Scholar 

  32. Ewaisha R, Panicker G, Maranian P, Unger ER, Anderson KS. Serum immune profiling for early detection of cervical. Theranostics. 2017;7:3814–23.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sharma B, Sharma R, Smith C, Aurelian L. Prevalence of serum antibodies to LA-1 oncoprotein, herpes simplex virus type-2 glycoprotein and human papillomavirus type 16 transactivator (E2) protein among Indian women with cervical neoplasia. Indian J Exp Biol. 1998;36:967–72.

    PubMed  CAS  Google Scholar 

  34. Zhang C, Ye L, Guan S, Jin S, Wang W, Sun S, et al. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumor Biol. 2014;35:2047–51.

    Article  CAS  Google Scholar 

  35. Looi K, Megliorino R, Shi F-D, Peng X-X, Chen Y, Zhang J-Y. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16:1105–10.

    PubMed  CAS  Google Scholar 

  36. Old LJ, Chen Y-T. New paths in human cancer serology. J Exp Med. 1998;187:1163–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Chen C, Huang Y, Zhang C, Liu T, Zheng H, Wan S, et al. Circulating antibodies to p16 protein-derived peptides in breast cancer. Mol Clin Oncol. 2015;3:591–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Jin Y, Guan S, Liu L, Sun S, Lee K-H, Wei J. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. Asia Pac J Clin Oncol. 2015;11.

  39. Pan X, Gao Y, Liu J, Liu C, Xia Y. Progress in studies on autoantibodies against tumor-associated antigens in hepatocellular carcinoma. Transl Cancer Res. 2016;5:845–59.

    Article  CAS  Google Scholar 

  40. Zhou S, Yue W, Fan Z, Du F, Liu B, Li B, et al. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus. 2014;27:790–7.

    Article  PubMed  CAS  Google Scholar 

  41. Marais DJ, Constant D, Allan B, Carrara H, Hoffman M, Shapiro S, et al. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. J Clin Microbiol. 2008;46:732–9.

    Article  PubMed  Google Scholar 

  42. Tjiong M, Out T, Schegget JT, Burger M, Van Der Vange N. Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: A review. Int J Gynecol Cancer. 2001;11:9–17.

    Article  PubMed  CAS  Google Scholar 

  43. Onda T, Carter JJ, Koutsky LA, Hughes JP, Lee S-K, Kuypers J, et al. Characterization of IgA response among women with incident HPV 16 infection. Virology. 2003;312:213–21.

    Article  PubMed  CAS  Google Scholar 

  44. ListÌ F, Candore G, Modica MA, Russo M, Lorenzo GD, Esposito-Pellitteri M, et al. A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci. 2006;1089:487–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This project was supported by Grant of Khon Kaen University (Grant numbers 551603, 564103 and 573003) and Faculty of Medicine, Khon Kaen University (Grant number I54141), and has received scholarship under the Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University, Thailand (Grant number 58443) and the Thailand Research Fund and Khon Kaen University through the Royal Golden Jubilee Ph.D. Program (Grant number PHD/0041/2557). We would like to acknowledge Prof. David Blair, for editing the MS via Publication Clinic KKU, Thailand.

Author information

Authors and Affiliations

  1. Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand

    Jureeporn Chuerduangphui, Chamsai Pientong, Ati Burassakarn & Tipaya Ekalaksananan

  2. Department of Medical Technology, Faculty of Medical Technology, Prince of Songkla University, Songkla, 90112, Thailand

    Piyawut Swangphon

  3. Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand

    Sanguanchoke Luanratanakorn & Pilaiwan Kleebkaow

  4. Department of Obstetrics and Gynecology, Khon Kaen Hospital, Khon Kaen, 40000, Thailand

    Ussanee Sangkomkamhang & Thumwadee Tungsiriwattana

  5. HPV & EBV and Carcinogenesis Research Group, Khon Kaen University, Khon Kaen, 40002, Thailand

    Jureeporn Chuerduangphui, Chamsai Pientong, Piyawut Swangphon, Sanguanchoke Luanratanakorn, Ussanee Sangkomkamhang, Thumwadee Tungsiriwattana, Pilaiwan Kleebkaow, Ati Burassakarn & Tipaya Ekalaksananan

Authors
  1. Jureeporn Chuerduangphui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chamsai Pientong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piyawut Swangphon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sanguanchoke Luanratanakorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ussanee Sangkomkamhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thumwadee Tungsiriwattana
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pilaiwan Kleebkaow
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ati Burassakarn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tipaya Ekalaksananan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tipaya Ekalaksananan.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

The sampling of human sera and cervical tissues was approved by the Khon Kaen University Ethics Committee for Human Research (No. HE531387) and the Khon Kaen Central Hospital Ethics Committee for Human Research (No. 20/04/2554), in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study, giving their authorization to access their clinical information, sera and tumor samples for research purpose.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chuerduangphui, J., Pientong, C., Swangphon, P. et al. Association of antibody to E2 protein of human papillomavirus and p16INK4A with progression of HPV-infected cervical lesions. Med Oncol 35, 93 (2018). https://doi.org/10.1007/s12032-018-1151-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1151-2

Keywords

Search

Navigation